Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular Completes 1-For-15 Reverse Stock Split

NEW YORK – HTG Molecular has completed a 1-for-15 reverse stock split of its outstanding common stock.

As a result of the split, effective with the open of the market on Monday, the firm's common stock is now trading on a split-adjusted basis.

Authorization for the reverse split was approved by the firm's stockholders at HTG's annual stockholder meeting in August, and subsequently approved by its board of directors last week. The number of authorized shares of common stock will be reduced to 26.7 million from 200 million.

The reverse stock split combined 15 pre-split shares of HTG's common stock outstanding into one share. The firm has not issued any fractional shares and is instead paying cash to stockholders with remaining fractional shares.  

In October 2019, Tucson, Arizona-based HTG received a notice of non-compliance Nasdaq indicating that it had failed to meet a listing requirement calling for a minimum closing bid of $1 per share.

HTG's stock was down about 2 percent at $4.19 in early-morning trading.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more